Tafamidis — Membership Pricing
Tafamidis is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Tafamidis Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $189.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Tafamidis
Tafamidis is a prescription medication. Ask your doctor if Tafamidis is right for you.
How to Check Tafamidis Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Tafamidis at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Metabolic
What Tafamidis is approved for (FDA label)
VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. ( 1 )
Source: Read the full FDA label on DailyMed. Label effective date: May 12, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Dosage forms and strengths for Tafamidis (FDA label)
VYNDAQEL is available as: • tafamidis meglumine 20 mg: yellow, opaque, oblong capsule, printed with "VYN 20" in red. VYNDAMAX is available as: • tafamidis 61 mg: reddish brown, opaque, oblong capsule, printed with "VYN 61" in white. Capsules: Tafamidis meglumine 20 mg and tafamidis 61 mg. ( 3 )
Source: FDA prescribing information (DailyMed). Set ID: 1b4121ee-a733-4456-a917-be2603477839. SPL document ID: 67f1031d-c298-4cf9-9051-bb8f99e56442. Label effective date: May 12, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Tafamidis (FDA label)
To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data reflect exposure of 377 ATTR-CM patients to 20 mg or 80 mg (administered as four 20-mg capsules) of VYNDAQEL administered daily for an average of 24.5 months (ranging from 1 day to 111 months).
Source: FDA prescribing information (DailyMed). Set ID: 1b4121ee-a733-4456-a917-be2603477839. SPL document ID: 67f1031d-c298-4cf9-9051-bb8f99e56442. Label effective date: May 12, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Tafamidis (FDA label)
None. None. ( 4 )
Source: FDA prescribing information (DailyMed). Set ID: 1b4121ee-a733-4456-a917-be2603477839. SPL document ID: 67f1031d-c298-4cf9-9051-bb8f99e56442. Label effective date: May 12, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Tafamidis (FDA label)
7.1 BCRP Substrates Tafamidis inhibits breast cancer resistant protein (BCRP) in humans [see Clinical Pharmacology (12.3) ] . Coadministration of tafamidis and drugs that are BCRP substrates may increase the exposure of substrates of this transporter (e.g., methotrexate, rosuvastatin, imatinib) and the risk of the substrate-related toxicities. Monitor for signs of BCRP substrate-related toxicities and modify dosage of the substrate if appropriate.
Source: FDA prescribing information (DailyMed). Set ID: 1b4121ee-a733-4456-a917-be2603477839. SPL document ID: 67f1031d-c298-4cf9-9051-bb8f99e56442. Label effective date: May 12, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.